First-Line Keytruda Treatment May Support Longer Mesothelioma Survival

first-line Keytruda treatment

New data suggests first-line Keytruda treatment helps lung cancer patients more than chemotherapy – even if chemotherapy patients add Keytruda later. The news is likely to have implications for people with pleural mesothelioma, too. German researchers presented the data earlier this week at the World Lung Cancer Conference in Barcelona.  The presentation was based on three years of the KEYNOTE-024 trial. The trial focused on lung cancer. But Keytruda is also an up-and-coming drug for malignant pleural mesothelioma. Pleural mesothelioma is a lung-related cancer similar to non-small cell lung cancer.  Blocking PD-L1 with First-Line Keytruda Treatment Keytruda is the brand name for pembrolizumab. It is an immune checkpoint inhibitor that blocks a protein called PD-L1. To be eligible for first-line … Continue reading First-Line Keytruda Treatment May Support Longer Mesothelioma Survival »

Lung Cancer Blood Test: Can it Find Early Mesothelioma?

lung cancer blood test for mesothelioma

Mesothelioma patients and their doctors may have reason to be optimistic about a new lung cancer blood test. A random trial of more than 12,000 high-risk people in Scotland shows the EarlyCDT test combined with CT imaging can detect cancer early. Earlier diagnosis is likely to lead to longer survival of lung cancers like pleural mesothelioma. Researchers presented their findings on the new lung cancer blood test at a global conference this week in Spain. Largest Lung Cancer Trial As in the US, lung cancer is the biggest cancer killer in Scotland. Pleural mesothelioma is a form of lung cancer. Although it is rare, mesothelioma is more common in the UK than in other parts of the world. This is … Continue reading Lung Cancer Blood Test: Can it Find Early Mesothelioma? »

New Hope for Relapsed Pleural Mesothelioma?

relapsed pleural mesothelioma

There is new evidence that adding a drug called vorinostat to immunotherapy might help relapsed pleural mesothelioma patients.  The new study comes from the Moffitt Cancer Center in Tampa. It focused on patients with non-small cell lung cancer. Non-small cell lung cancer is similar to pleural mesothelioma in many ways.  The study found that patients who received vorinostat along with an immune checkpoint inhibitor had better results. The findings could be good news for relapsed pleural mesothelioma patients, too. Different Immunotherapy Drugs Vorinostat is sold under the brand name Zolinza. It is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors alter the way proteins are expressed inside cells. They also stimulate the immune system.  Immune checkpoint inhibitors (ICIs) like Keytruda also … Continue reading New Hope for Relapsed Pleural Mesothelioma? »

Effect of Chemotherapy on Immunotherapy for Mesothelioma

effect of chemotherapy on immunotherapy

Belgian scientists say they are still not sure about the effect of chemotherapy on immunotherapy for mesothelioma. They reached that conclusion after testing several different chemotherapy drugs on mesothelioma cells in the lab. The combination of chemotherapy and immunotherapy is “chemoimmunotherapy”. It aims to harness the unique powers of each treatment approach. A meta-analysis last May called chemoimmunotherapy the “next frontier” in mesothelioma treatment.  But the new Belgian study on the effect of chemotherapy on immunotherapy highlights how much doctors still do not know about the combo. Immune Checkpoints Are the Key When it is working properly, the immune system is supposed to find and kill cancer cells before they become mesothelioma tumors. But mesothelioma cells can hide from the … Continue reading Effect of Chemotherapy on Immunotherapy for Mesothelioma »

Pleural Mesothelioma Rates Remain Stagnant As Survival Improves

pleural mesothelioma rates

A new report shows pleural mesothelioma rates in the US have failed to decline as they were predicted to do, but survival is improving slightly.  The US government began to implement tighter restrictions on asbestos in the 1970s. Researchers at the Cleveland Clinic say original projections had the incidence of pleural mesothelioma peaking in the early 2000s as a result. Pleural mesothelioma rates were supposed to decline after that. But numbers from the National Cancer Database (NCDB) tell a different story. They suggest that, while mesothelioma survival is improving, incidence of asbestos cancer are not. Asbestos and Malignant Mesothelioma Malignant mesothelioma is the most serious of a range of illnesses caused by asbestos. Pleural mesothelioma is the most common type … Continue reading Pleural Mesothelioma Rates Remain Stagnant As Survival Improves »

Curcumin Supplement Delays Mesothelioma Tumor Growth in Mice

curcumin supplement

Italian researchers say a curcumin supplement containing a compound found in black pepper slowed the growth of mesothelioma tumors in mice. The commercially available supplement is called Curcumin-C3complex/Bioperine. This is the first time this formulation has been studied for malignant mesothelioma.  Lab-grown human mesothelioma cells stopped growing when scientists treated them with the curcumin supplement. The treatment did the same in live mice.  The researchers suggest that the curcumin supplement may work synergistically with standard treatments.  What is in Curcumin-C3complex/Bioperine? Curcumin is the most bioactive compound in turmeric. Turmeric is the spice that gives curry its bright yellow color.  Several scientific studies suggest that curcumin and other curcuminoid compounds in turmeric have powerful health benefits. These compounds are anti-inflammatory and … Continue reading Curcumin Supplement Delays Mesothelioma Tumor Growth in Mice »

Isolated Thoracic Perfusion for Mesothelioma Symptom Relief

isolated thoracic perfusion for mesothelioma

A new study suggests that a treatment called isolated thoracic perfusion could help alleviate some of the worst symptoms of malignant pleural mesothelioma. Isolated thoracic perfusion is a method for circulating medicine in just one area of the body. When doctors circulated chemotherapy drugs in the chests of people with pleural mesothelioma, their symptoms went away for several months.  Now, the team says it is time to test the technique in a bigger pool of mesothelioma patients.  The Theory Behind ITP Pleural mesothelioma is a membrane cancer that occurs in the chest. Chemotherapy drugs like Alimta can be powerful weapons against pleural mesothelioma. But they can also damage healthy tissues.  When healthy tissues are damaged by chemotherapy, mesothelioma patients can … Continue reading Isolated Thoracic Perfusion for Mesothelioma Symptom Relief »

Keto Diet for Mesothelioma Not Advised Despite New Research

keto diet for mesothelioma

New research suggests a diet low in carbs and sugar may slow the growth of certain kinds of cancer cells. The news may have mesothelioma patients wondering about the value of the keto diet for mesothelioma, too.  The new study appears in the most recent issue of the journal Cell Reports. Researchers fed a restrictive ketogenic diet to mice with a certain kind of lung cancer. They also gave them a drug to keep the kidneys from absorbing extra glucose. The trial was not focused specifically on the keto diet for mesothelioma. But the findings do show that sugar and certain cancers do not mix.  What is the Ketogenic Diet? The ketogenic – or “keto” – diet is very low … Continue reading Keto Diet for Mesothelioma Not Advised Despite New Research »

New Mesothelioma Immunotherapy Trial Now Underway at Baylor

mesothelioma immunotherapy trial

Cancer researchers at Baylor College of Medicine have launched a new mesothelioma immunotherapy trial. The trial combines the cancer drug Opdivo (nivolumab) with injections of a modified virus called MTG201. Baylor scientists are hoping to recruit 12 pleural mesothelioma patients whose cancer has come back after chemotherapy.  The treatment combination appeared to work well in mice with mesothelioma. If it works as well in people, this new mesothelioma immunotherapy trial could change the outlook for many people with malignant mesothelioma.  How the New Mesothelioma Immunotherapy Trial Will Work Opdivo is the brand name for nivolumab. It blocks a protein called PD-1 in cancer cells. PD-1 is one of the ways that mesothelioma cells evade the immune system. Opdivo is often … Continue reading New Mesothelioma Immunotherapy Trial Now Underway at Baylor »

Cediranib for Mesothelioma: VEGF Inhibitor Fails Another Trial

cediranib for mesothelioma

Cediranib for mesothelioma appears to be ruled out by another failed clinical trial.  A new study led by MD Anderson researchers concludes that the VEGF inhibitor causes too many side effects for not enough survival benefit.  It is a blow to researchers hoping to use cediranib for mesothelioma patients on chemotherapy.  Cutting Off Tumor Blood Supply Cediranib is an oral drug made by AstraZeneca. It is part of a class of drugs called VEGF inhibitors. Vascular endothelial growth factor (VEGF) is a signal protein that stimulates blood vessel formation in tumors. Research shows that mesothelioma patients who have higher serum levels of VEGF have a lower chance of survival.  VEGF inhibitors like cediranib latch onto VEGF receptors inside mesothelioma cells. … Continue reading Cediranib for Mesothelioma: VEGF Inhibitor Fails Another Trial »

Get your free copy of
“Surviving Mesothelioma” Today!